NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
about
Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaThe HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in noAssociation between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases.Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.NOTCH1 Aberrations in Chronic Lymphocytic Leukemia.
P2860
Q26783600-4A469D95-9A9D-4E56-B00F-81F02F7F640BQ33913962-97F3FAF0-1309-4F7D-B90B-23DFA463E5A4Q35741703-EE512FB8-D37F-48C0-BC81-C5D47F97A3E1Q40784167-3BE6A9F1-2D90-499F-A030-A6950704587BQ41095380-DE87B9B7-DA27-4681-A32E-28F4BE223BC3Q50025029-0D7A48FB-AF3F-460C-8067-42D54B218AA3Q50569242-614EFF41-F606-41BB-BA3F-F63AC2E56144Q51093052-ABE3632D-30A7-439E-A035-7897B7B7E39AQ52638918-16FB63AE-87C7-44B8-AE8E-2D0812D2D489Q52675362-97A94330-D54C-4611-9210-F788B28DCAAEQ52931736-5501D328-23FA-44F5-9952-B3FA740F0F74Q55668973-80642EE0-C4AF-4D2B-A2A7-3AB4C1351B89
P2860
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
NOTCH1 mutations identify a ch ...... n and consolidation treatment.
@en
NOTCH1 mutations identify a ch ...... n and consolidation treatment.
@nl
type
label
NOTCH1 mutations identify a ch ...... n and consolidation treatment.
@en
NOTCH1 mutations identify a ch ...... n and consolidation treatment.
@nl
prefLabel
NOTCH1 mutations identify a ch ...... n and consolidation treatment.
@en
NOTCH1 mutations identify a ch ...... n and consolidation treatment.
@nl
P2093
P2860
P50
P1433
P1476
NOTCH1 mutations identify a ch ...... n and consolidation treatment.
@en
P2093
Dario Ragusa
Davide Rossi
Francesca Maria Rossi
Luca Maurillo
Michele Dal Bo
Pasquale Niscola
Pietro Bulian
P2860
P304
P356
10.1007/S00277-014-2117-X
P50
P577
2014-06-13T00:00:00Z